Linked Life Data

10439367

Source:http://linkedlifedata.com/resource/pubmed/id/10439367

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3-4
pubmed:dateCreated
1999-9-21
pubmed:abstractText
The value of high-dose therapy with autologous stem cell transplantation as first-line therapy in poor prognosis Hodgkin's disease is controversial and we report the results of evaluation of twenty-six patients who were selected for this procedure from February 1989 to July 1994. They were all patients with stage IV at diagnosis with at least two other unfavourable characteristics, i.e. B symptoms, mediastinal mass greater than 0.45 of the thoracic diameter, two or more extranodal sites, bone marrow involvement, inguinal node involvement, serum lactic dehydrogenase greater than 400 IU/L, or low hematocrit. At the time of transplantation, 19 patients were in complete remission and 10 were in partial remission > or = 50%. Procedure-related mortality in the first 90 days post-graft was 7% overall. Of the 24 evaluable patients, 22 (92%) were assessed as complete responders, and 2 (8%) had progression of disease at 6 months. The actuarial overall survival (OS), disease-free survival (DFS) and event-free survival (EFS) at 5 years were 69%, 79% and 58%, respectively. The Cox proportional hazards model was used to assess prognostic factors. In univariate analysis only one prognostic factor was found to be significantly associated with improved DFS, i.e. low serum lactic dehydrogenase (LDH) (DFS at 5 years: 92% if LDH < 400 IU/L vs 44% if LDH 400 IU/L, P = 0.007). DFS rates between first complete remission and first partial remission groups were not significantly different (DFS at 5 years: 87% vs 66%, p = 0.15). These first results are encouraging but randomized studies are needed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1042-8194
pubmed:author
pubmed:issnType
Print
pubmed:volume
34
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
305-13
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed-meshheading:10439367-Adolescent, pubmed-meshheading:10439367-Adult, pubmed-meshheading:10439367-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:10439367-Bleomycin, pubmed-meshheading:10439367-Disease-Free Survival, pubmed-meshheading:10439367-Doxorubicin, pubmed-meshheading:10439367-Etoposide, pubmed-meshheading:10439367-Female, pubmed-meshheading:10439367-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:10439367-Hodgkin Disease, pubmed-meshheading:10439367-Humans, pubmed-meshheading:10439367-Ifosfamide, pubmed-meshheading:10439367-Male, pubmed-meshheading:10439367-Mechlorethamine, pubmed-meshheading:10439367-Middle Aged, pubmed-meshheading:10439367-Mitoguazone, pubmed-meshheading:10439367-Outcome Assessment (Health Care), pubmed-meshheading:10439367-Prednisolone, pubmed-meshheading:10439367-Prednisone, pubmed-meshheading:10439367-Procarbazine, pubmed-meshheading:10439367-Prognosis, pubmed-meshheading:10439367-Prospective Studies, pubmed-meshheading:10439367-Vinblastine, pubmed-meshheading:10439367-Vincristine
pubmed:year
1999
pubmed:articleTitle
Intensive therapy with autologous stem cell transplantation as first-line therapy in poor-risk Hodgkin's disease and analysis of predictive factors of outcome.
pubmed:affiliation
Department of Hematology/Oncology, Bretonneau Hospital, Tours, France.
pubmed:publicationType
Journal Article, Clinical Trial